Trump administration reportedly considering temporary sale of unapproved peptides
The Trump administration appears inclined to allow a limited, temporary market for certain unapproved peptides, according to The Washington Post. This potential policy shift follows recent FDA hearings in July about whether compounding pharmacies should be permitted to sell such substances without full regulatory approval. Though the specific types of peptides and exact timing remain unclear, the move is said to offer political benefits by addressing demand from users who currently rely on gray-market sources for these compounds. Peptides are often used for performance enhancement or medical purposes but require FDA clearance before commercial sale in most cases. This development could signal a broader regulatory shift under Trump’s leadership and may impact both pharmaceutical companies and compounding pharmacies, depending on how the policy is implemented.
Topics: compounding pharmacies gray market peptides Trump administration